Effects of the CYP 2D6 Genotype and Cigarette Smoking on the Steady‐State Plasma Concentrations of Fluvoxamine and Its Major Metabolite Fluvoxamino Acid in Japanese Depressed Patients
暂无分享,去创建一个
K. Otani | H. Higuchi | Keizo Yoshida | Hitoshi Takahashi | T. Ohkubo | R. Shimoyama | T. Fukasawa | T. Aoshima | T. Shimizu | G. Gerstenberg | Y. Murata
[1] L. Bertilsson,et al. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype , 1996, Psychopharmacology.
[2] G. Alfredsson,et al. Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses , 2004, Psychopharmacology.
[3] N. Yasui-Furukori,et al. Clinical implications of pharmacogenetics of antidepressants , 2002 .
[4] L. Bertilsson,et al. Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) , 2002, Clinical pharmacology and therapeutics.
[5] O. Spigset,et al. The major fluvoxamine metabolite in urine is formed by CYP2D6 , 2001, European Journal of Clinical Pharmacology.
[6] L. Bertilsson,et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. , 2001, British journal of clinical pharmacology.
[7] T. Someya,et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. , 2000, Journal of clinical psychopharmacology.
[8] F. Holsboer,et al. Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption , 2000, Neuropsychopharmacology.
[9] K. Otani,et al. Pharmacogenetics of classical and new antipsychotic drugs. , 2000, Therapeutic drug monitoring.
[10] C. Beasley,et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.
[11] T. Someya,et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. , 1999, Therapeutic drug monitoring.
[12] T. Kamataki,et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.
[13] K. Otani,et al. Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia , 1999, Clinical pharmacology and therapeutics.
[14] O. Spigset,et al. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance , 1999, European Journal of Clinical Pharmacology.
[15] H. Wetzel,et al. Nonlinear pharmacokinetics of fluvoxamine and gender differences. , 1998, Therapeutic drug monitoring.
[16] O. Spigset,et al. Non-linear fluvoxamine disposition. , 1998, British journal of clinical pharmacology.
[17] L. Bertilsson,et al. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. , 1997, Journal of clinical psychopharmacology.
[18] K. Otani,et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. , 1997, Pharmacogenetics.
[19] O. Spigset,et al. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms , 1997, European Journal of Clinical Pharmacology.
[20] O. Wiborg,et al. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. , 1996, Therapeutic drug monitoring.
[21] C. Alm,et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity , 1996, Clinical pharmacology and therapeutics.
[22] O. Wiborg,et al. Steady‐state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism , 1996, Clinical pharmacology and therapeutics.
[23] O. Spigset,et al. A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics. , 1996, Journal of Clinical Psychopharmacology.
[24] L. Bertilsson,et al. Polymorphic Drug Oxidation , 1996 .
[25] O. Spigset,et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans , 1995, Clinical pharmacology and therapeutics.
[26] K. Otani,et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. , 1995, International clinical psychopharmacology.
[27] O. Andreassen,et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. , 1995, Pharmacogenetics.
[28] A. Chamberlain,et al. Dose-dependent caffeine pharmacokinetics during severe sleep deprivation in humans. , 1995, International journal of clinical pharmacology and therapeutics.
[29] M. Ingelman-Sundberg,et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.
[30] D. Schrenk,et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.
[31] G. Plosker,et al. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. , 1993, Drugs.
[32] J. Rabe-Jabłońska,et al. [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.
[33] K. Otani,et al. Steady‐State Plasma Concentrations of Mianserin and Its Major Active Metabolite, Desmethylmianserin , 1993, Therapeutic drug monitoring.
[34] M. Raghoebar,et al. Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects , 1992, Therapeutic drug monitoring.
[35] H. Wetzel,et al. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. , 1992, Clinical chemistry.
[36] K. Otani,et al. Steady‐state serum kinetics of zotepine , 1992 .
[37] U. Meyer,et al. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. , 1991, Methods in enzymology.
[38] W. Fleischhacker,et al. Influence of patient-related variables on clozapine plasma levels. , 1990, The American journal of psychiatry.
[39] M. Jann,et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients , 1985, Biological Psychiatry.
[40] J. Miners,et al. Nonlinear Metabolic Disposition of Theophylline , 1984, Therapeutic drug monitoring.
[41] V. Claassen. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. , 1983, British journal of clinical pharmacology.